valproic acid has been researched along with Thyroid Neoplasms in 25 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study investigated the mechanism underlying the antitumor activity of the histone deacetylases inhibitor valproic acid (VPA), alone and in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative (HS-1200), or the proteasome inhibitor lactacystin on cultured anaplastic thyroid carcinoma KAT-18 cells." | 7.75 | Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin. ( Kang, DY; Kim, SH; Kim, TH; Park, KJ; Park, MK; Suh, H; Yoo, YH, 2009) |
| "The present study investigated the effect of valproic acid (VPA) on the inhibition of RET signaling and induction of apoptosis in human thyroid carcinoma cells." | 3.81 | Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA). ( Dong, JD; Xu, D; Xu, Y; Ye, B; Zhang, Y; Zhang, YL; Zhu, SJ, 2015) |
| "The present study investigated the mechanism underlying the antitumor activity of the histone deacetylases inhibitor valproic acid (VPA), alone and in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative (HS-1200), or the proteasome inhibitor lactacystin on cultured anaplastic thyroid carcinoma KAT-18 cells." | 3.75 | Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin. ( Kang, DY; Kim, SH; Kim, TH; Park, KJ; Park, MK; Suh, H; Yoo, YH, 2009) |
| "The introduction of paclitaxel into multimodal therapy for anaplastic thyroid carcinoma has failed to improve overall survival." | 3.74 | Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. ( Boccuzzi, G; Catalano, MG; Fortunati, N; Poli, R; Pugliese, M, 2007) |
| "Valproic acid does not increase radioiodine uptake and does not have anticancer activity in patients with advanced, radioiodine-negative thyroid cancer of follicular cell origin." | 2.84 | A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin. ( Kebebew, E; Merkel, R; Neychev, V; Nilubol, N; Patel, D; Reynolds, JC; Sadowski, SM; Yang, L, 2017) |
| "The incidence of thyroid cancer continues to increase and this neoplasia remains the most common endocrine malignancy." | 2.48 | Novel molecular targeted therapies for refractory thyroid cancer. ( Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES, 2012) |
| "Valproic acid (VA) is a clinically available histone deacetylase inhibitor with a well-documented side effect profile." | 1.91 | Valproic acid radiosensitizes anaplastic thyroid cells through a decrease of the DNA damage repair capacity. ( Campos-Haedo, M; Cremaschi, G; Dagrosa, MA; Durán, HA; Grissi, C; Ibañez, IL; Juvenal, GJ; Oglio, R; Perona, M; Rosemblit, C; Thomasz, L; Villaverde, MS, 2023) |
| "Chronic post-hypoxic myoclonus is a condition in which the predominant clinical picture is myoclonus following hypoxic brain damage, usually due to cardiorespiratory arrest." | 1.62 | [Response to perampanel in a patient with chronic post-hypoxic myoclonus]. ( de Toledo, M; Muro-García, I; Pastor, J; Vega, L; Vieira, A, 2021) |
| "HDACi radiosensitized thyroid cancer cells as evidenced by the reduction of survival fraction, whereas they had no effect in the normal cells." | 1.48 | Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone deacetylase sodium butyrate and valproic acid. ( Cremaschi, GA; Dagrosa, MA; Juvenal, GJ; Perona, M; Pisarev, MA; Rodriguez, C; Rosemblit, C; Rossich, L; Thomasz, L, 2018) |
| "Anaplastic thyroid cancer is an aggressive and highly lethal cancer for which conventional therapies have proved ineffective." | 1.43 | Generation of Novel Thyroid Cancer Stem-Like Cell Clones: Effects of Resveratrol and Valproic Acid. ( Chen, H; Chen, J; Hardin, H; Harrison, AD; Larrain, C; Lloyd, RV; Yu, XM; Zhang, R, 2016) |
| "Valproic acid (VA) is an anticonvulsant that inhibits histone deacetylase activity at nontoxic concentrations." | 1.33 | Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. ( Chung, WY; Clark, OH; Duh, QY; Kebebew, E; Shen, WT; Wong, MG; Wong, TS, 2005) |
| "In poorly differentiated thyroid cancer, molecular characteristics are reported to be lost such as to cause insensitivity of the tumor to radiometabolic therapy." | 1.32 | Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. ( Arena, K; Boccuzzi, G; Brignardello, E; Catalano, MG; Fortunati, N; Piovesan, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 13 (52.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perona, M | 2 |
| Ibañez, IL | 1 |
| Thomasz, L | 2 |
| Villaverde, MS | 1 |
| Oglio, R | 1 |
| Rosemblit, C | 2 |
| Grissi, C | 1 |
| Campos-Haedo, M | 1 |
| Dagrosa, MA | 2 |
| Cremaschi, G | 1 |
| Durán, HA | 1 |
| Juvenal, GJ | 2 |
| Muro-García, I | 1 |
| Vieira, A | 1 |
| Vega, L | 1 |
| Pastor, J | 1 |
| de Toledo, M | 1 |
| Rossich, L | 1 |
| Rodriguez, C | 1 |
| Pisarev, MA | 1 |
| Cremaschi, GA | 1 |
| Massimino, M | 1 |
| Tirrò, E | 1 |
| Stella, S | 1 |
| Frasca, F | 1 |
| Vella, V | 1 |
| Sciacca, L | 1 |
| Pennisi, MS | 1 |
| Vitale, SR | 1 |
| Puma, A | 1 |
| Romano, C | 1 |
| Manzella, L | 1 |
| Kurzrock, R | 1 |
| Atkins, J | 1 |
| Wheler, J | 1 |
| Fu, S | 1 |
| Naing, A | 1 |
| Busaidy, N | 1 |
| Hong, D | 1 |
| Sherman, S | 1 |
| Cha, HY | 2 |
| Lee, BS | 2 |
| Kang, S | 1 |
| Shin, YS | 2 |
| Chang, JW | 2 |
| Sung, ES | 1 |
| Kim, YS | 2 |
| Choi, JW | 1 |
| Kim, JH | 1 |
| Kim, CH | 2 |
| Schwertheim, S | 1 |
| Worm, K | 1 |
| Schmid, KW | 1 |
| Sheu-Grabellus, SY | 1 |
| Xu, Y | 1 |
| Xu, D | 1 |
| Zhu, SJ | 1 |
| Ye, B | 1 |
| Dong, JD | 1 |
| Zhang, YL | 1 |
| Zhang, Y | 2 |
| Park, JK | 1 |
| Han, JH | 1 |
| Byeon, HK | 1 |
| Hardin, H | 1 |
| Yu, XM | 1 |
| Harrison, AD | 1 |
| Larrain, C | 1 |
| Zhang, R | 1 |
| Chen, J | 1 |
| Chen, H | 4 |
| Lloyd, RV | 1 |
| Aebischer, B | 1 |
| Elsig, S | 1 |
| Taeymans, J | 1 |
| Pomp, S | 1 |
| Kuhness, D | 1 |
| Barcaro, G | 1 |
| Sementa, L | 1 |
| Mankad, V | 1 |
| Fortunelli, A | 1 |
| Sterrer, M | 1 |
| Netzer, FP | 1 |
| Surnev, S | 1 |
| Schmieder, AH | 1 |
| Caruthers, SD | 1 |
| Keupp, J | 1 |
| Wickline, SA | 1 |
| Lanza, GM | 1 |
| Lowe, J | 1 |
| Wodarcyk, AJ | 1 |
| Floyd, KT | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Swager, SA | 1 |
| Chadwick, JA | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Janssen, PM | 1 |
| Rafael-Fortney, JA | 1 |
| Alcalay, RN | 1 |
| Levy, OA | 1 |
| Wolf, P | 1 |
| Oliva, P | 1 |
| Zhang, XK | 1 |
| Waters, CH | 1 |
| Fahn, S | 1 |
| Kang, U | 1 |
| Liong, C | 1 |
| Ford, B | 1 |
| Mazzoni, P | 1 |
| Kuo, S | 1 |
| Johnson, A | 1 |
| Xiong, L | 1 |
| Rouleau, GA | 1 |
| Chung, W | 1 |
| Marder, KS | 1 |
| Gan-Or, Z | 1 |
| Kamei, K | 1 |
| Terao, T | 1 |
| Katayama, Y | 1 |
| Hatano, K | 1 |
| Kodama, K | 1 |
| Shirahama, M | 1 |
| Sakai, A | 1 |
| Hirakawa, H | 1 |
| Mizokami, Y | 1 |
| Shiotsuki, I | 1 |
| Ishii, N | 1 |
| Inoue, Y | 1 |
| Akboga, MK | 1 |
| Yayla, C | 1 |
| Balci, KG | 1 |
| Ozeke, O | 1 |
| Maden, O | 1 |
| Kisacik, H | 1 |
| Temizhan, A | 1 |
| Aydogdu, S | 1 |
| Zhu, J | 2 |
| Ying, SH | 1 |
| Feng, MG | 1 |
| Zhang, XG | 1 |
| Li, H | 1 |
| Wang, L | 1 |
| Hao, YY | 1 |
| Liang, GD | 1 |
| Ma, YH | 1 |
| Yang, GS | 1 |
| Hu, JH | 1 |
| Pfeifer, L | 1 |
| Goertz, RS | 1 |
| Neurath, MF | 1 |
| Strobel, D | 1 |
| Wildner, D | 1 |
| Lin, JT | 1 |
| Yang, XN | 1 |
| Zhong, WZ | 1 |
| Liao, RQ | 1 |
| Dong, S | 1 |
| Nie, Q | 1 |
| Weng, SX | 1 |
| Fang, XJ | 1 |
| Zheng, JY | 1 |
| Wu, YL | 1 |
| Řezanka, T | 1 |
| Kaineder, K | 1 |
| Mezricky, D | 1 |
| Řezanka, M | 1 |
| Bišová, K | 1 |
| Zachleder, V | 1 |
| Vítová, M | 1 |
| Rinker, JA | 1 |
| Marshall, SA | 1 |
| Mazzone, CM | 1 |
| Lowery-Gionta, EG | 1 |
| Gulati, V | 1 |
| Pleil, KE | 1 |
| Kash, TL | 1 |
| Navarro, M | 1 |
| Thiele, TE | 1 |
| Huang, Y | 1 |
| Jin, Z | 1 |
| Li, X | 1 |
| Li, B | 1 |
| Xu, P | 1 |
| Huang, P | 1 |
| Liu, C | 1 |
| Fokdal, L | 1 |
| Sturdza, A | 1 |
| Mazeron, R | 1 |
| Haie-Meder, C | 1 |
| Tan, LT | 1 |
| Gillham, C | 1 |
| Šegedin, B | 1 |
| Jürgenliemk-Schultz, I | 1 |
| Kirisits, C | 1 |
| Hoskin, P | 1 |
| Pötter, R | 1 |
| Lindegaard, JC | 1 |
| Tanderup, K | 1 |
| Levin, DE | 1 |
| Schmitz, AJ | 1 |
| Hines, SM | 1 |
| Hines, KJ | 1 |
| Tucker, MJ | 1 |
| Brewer, SH | 1 |
| Fenlon, EE | 1 |
| Álvarez-Pérez, S | 1 |
| Blanco, JL | 1 |
| Peláez, T | 1 |
| Martínez-Nevado, E | 1 |
| García, ME | 1 |
| Puckerin, AA | 1 |
| Chang, DD | 1 |
| Subramanyam, P | 1 |
| Colecraft, HM | 1 |
| Dogan, H | 1 |
| Coteli, E | 1 |
| Karatas, F | 1 |
| Ceylan, O | 1 |
| Sahin, MD | 1 |
| Akdamar, G | 1 |
| Kryczyk, A | 1 |
| Żmudzki, P | 1 |
| Hubicka, U | 1 |
| Giovannelli, D | 1 |
| Chung, M | 1 |
| Staley, J | 1 |
| Starovoytov, V | 1 |
| Le Bris, N | 1 |
| Vetriani, C | 1 |
| Chen, W | 1 |
| Wu, L | 1 |
| Liu, X | 1 |
| Shen, Y | 1 |
| Liang, Y | 1 |
| Tan, H | 1 |
| Yang, Y | 1 |
| Liu, Q | 1 |
| Wang, M | 1 |
| Liu, L | 1 |
| Wang, X | 1 |
| Liu, B | 1 |
| Liu, GH | 1 |
| Zhu, YJ | 1 |
| Wang, JP | 1 |
| Che, JM | 1 |
| Chen, QQ | 1 |
| Chen, Z | 1 |
| Maucksch, U | 1 |
| Runge, R | 1 |
| Wunderlich, G | 1 |
| Freudenberg, R | 1 |
| Naumann, A | 1 |
| Kotzerke, J | 1 |
| Nilubol, N | 1 |
| Merkel, R | 1 |
| Yang, L | 1 |
| Patel, D | 1 |
| Reynolds, JC | 1 |
| Sadowski, SM | 1 |
| Neychev, V | 1 |
| Kebebew, E | 3 |
| Greenblatt, DY | 1 |
| Cayo, MA | 1 |
| Adler, JT | 2 |
| Ning, L | 2 |
| Haymart, MR | 1 |
| Kunnimalaiyaan, M | 2 |
| Noguchi, H | 1 |
| Yamashita, H | 1 |
| Murakami, T | 1 |
| Hirai, K | 1 |
| Noguchi, Y | 1 |
| Maruta, J | 1 |
| Yokoi, T | 1 |
| Noguchi, S | 1 |
| Catalano, MG | 5 |
| Pugliese, M | 4 |
| Poli, R | 4 |
| Bosco, O | 3 |
| Bertieri, R | 1 |
| Fortunati, N | 5 |
| Boccuzzi, G | 5 |
| Xiao, X | 1 |
| Kim, TH | 1 |
| Yoo, YH | 1 |
| Kang, DY | 1 |
| Suh, H | 1 |
| Park, MK | 1 |
| Park, KJ | 1 |
| Kim, SH | 1 |
| Hottinger, DG | 1 |
| Mitmaker, EJ | 1 |
| Griff, NJ | 1 |
| Grogan, RH | 1 |
| Sarkar, R | 1 |
| Duh, QY | 2 |
| Clark, OH | 2 |
| Shen, WT | 2 |
| Perez, CA | 1 |
| Santos, ES | 1 |
| Arango, BA | 1 |
| Raez, LE | 1 |
| Cohen, EE | 1 |
| Arena, K | 1 |
| Brignardello, E | 1 |
| Piovesan, A | 1 |
| Costantino, L | 1 |
| Wong, TS | 1 |
| Chung, WY | 1 |
| Wong, MG | 1 |
| Mastrocola, R | 1 |
| Aragno, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies[NCT00215605] | Phase 1 | 85 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Phase I Study of Tipifarnib (R115777) and Sorafenib (BAY 43-9006) in Patients With Biopsiable Advanced Cancers[NCT00244972] | Phase 1 | 74 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma[NCT00121680] | Phase 1 | 115 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Multi-Arm Complete Phase 1 Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor[NCT00495872] | Phase 1 | 204 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Origin[NCT01182285] | Phase 2 | 13 participants (Actual) | Interventional | 2010-09-24 | Completed | ||
| PLA General Hospital[NCT05920512] | Phase 1/Phase 2 | 10 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT01182285)
Timeframe: Date treatment consent signed to date off study, approximately 41 months and 11 days
| Intervention | Participants (Count of Participants) |
|---|---|
| All Participants | 8 |
Best overall response was assessed by radioiodine uptake. Complete response (CR) is increased Rai (radioiodine) uptake on post- valproic acid therapy at week 10, AND a decrease in Tg (thyroglobulin ) level to less than 2 ng/ml (or a decrease in Tg-Ab (thyroglobulin antibodies) level to less than 2.0 IU/ml) at 10 weeks AND disappearance of all lesions at 16 weeks. Partial response (PR) is increased Rai uptake on post-valproic scan at week 10, OR a decreased Tg level (or a decrease in Tg Ab (Tg antibody) level by more than 20%) at 10 weeks AND 30% decrease in target lesion at 16 weeks. Stable disease (SD) is no change in RAI uptake AND Tg levels (or TG-Ab level) AND no significant change of lesions at 16 weeks. Progressive disease (PD) is tumor mass increases OR Tg levels (or Tg-Ab levels) increases over 10 weeks OR at least 20% increase in target lesion at 16 weeks. (NCT01182285)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Unknown | |
| B2 - Phase 2 Schedule 2 (No Increased Radiiodine Uptake) | 0 | 0 | 1 | 6 | 1 |
NIS (Na/I-symporter) Expression is assessed by quantitative reverse transcription (RT) polymerase chain reaction (PCR) and immunohistochemistry (IHC). NIS mRNA expression was measured by quantitative RT PCR from biopsy samples. (NCT01182285)
Timeframe: Entry to study and after 10 weeks of treatment
| Intervention | percent expression (Median) | |
|---|---|---|
| Pre-treatment NIS expression (relative to GAPDH) | Post-treatment NIS expression (relative to GAPDH) | |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | 21 | 25 |
Complete response (CR) is increased Rai uptake on post- valproic acid therapy at week 10, AND a decrease in Tg level to less than 2 ng/ml (or a decrease in Tg-Ab level to less than 2.0 IU/ml) at 10 weeks AND disappearance of all lesions at 16 weeks. Partial response (PR) is increased Rai uptake on post-valproic scan at week 10, OR a decreased Tg level (or a decrease in Tg Ab (Tg antibody) level by more than 20%) at 10 weeks AND 30% decrease in target lesion at 16 weeks. Stable disease (SD) is no change in RAI uptake AND Tg levels (or TG-Ab level) AND no significant change of lesions at 16 weeks. Progressive disease (PD) is tumor mass increases OR Tg levels (or Tg-Ab levels) increases over 10 weeks OR at least 20% increase in target lesion at 16 weeks. (NCT01182285)
Timeframe: Entry to study and after 10 weeks of treatment for Phase 1, and 10 weeks of treatment to 16 weeks of treatment for phase 2.
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tg start - >900 ng/ml | Tg start - 707 ng/ml | Tg start - 661 ng/ml | Tg start - 362 ng/ml | Tg start - 289 ng/ml | Tg start - 183 ng/ml | Tg start - 154 ng/ml | Tg start - 101 ng/ml | Tg start - 99 ng/ml | Tg start - 15.7 ng/ml | antiTg start - 142 IU/ml | antiTg start - 220 IU/ml | antiTg start - <20 IU/ml | Tg end - >900 ng/ml | Tg end - 749 ng/ml | Tg end - 702 ng/ml | Tg end - 630 ng/ml | Tg end - 480 ng/ml | Tg end - 362 ng/ml | Tg end - 204 ng/ml | Tg end - 184 ng/ml | Tg end - 183 ng/ml | Tg end - 128 ng/ml | Tg end - 61 ng/ml | Tg end - 10.8 ng/ml | Tg end - none | antiTg end - 338 IU/ml | anti Tg end - 220 IU/ml | antiTg end - 83 IU/ml | antiTg end - 80 IU/ml | anti Tg end - <20 IU/ml | antiTg end - none | RAI uptake pre-treatment - none | RAI uptake post treatment - none | |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | 6 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 | 4 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 5 | 1 | 13 | 10 |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
2 reviews available for valproic acid and Thyroid Neoplasms
| Article | Year |
|---|---|
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; A | 2016 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; B | 2012 |
2 trials available for valproic acid and Thyroid Neoplasms
| Article | Year |
|---|---|
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Female; Histone Deacetylase Inhibitors; Humans; | 2017 |
A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Female; Histone Deacetylase Inhibitors; Humans; | 2017 |
A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Female; Histone Deacetylase Inhibitors; Humans; | 2017 |
A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Female; Histone Deacetylase Inhibitors; Humans; | 2017 |
21 other studies available for valproic acid and Thyroid Neoplasms
| Article | Year |
|---|---|
Valproic acid radiosensitizes anaplastic thyroid cells through a decrease of the DNA damage repair capacity.
Topics: Cell Line, Tumor; DNA Damage; Histones; Humans; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Va | 2023 |
[Response to perampanel in a patient with chronic post-hypoxic myoclonus].
Topics: Anticonvulsants; Carcinoma, Papillary; Clonazepam; Drug Therapy, Combination; Electroencephalography | 2021 |
Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone deacetylase sodium butyrate and valproic acid.
Topics: Butyric Acid; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; DNA Damage; DNA Repair Enzymes; | 2018 |
Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells.
Topics: Animals; Azacitidine; Cells, Cultured; Combined Modality Therapy; DNA Methylation; DNA Modification | 2018 |
Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death.
Topics: Anticonvulsants; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Drug Resistanc | 2013 |
Valproic acid downregulates NF-κB p50 activity and IRAK-1 in a progressive thyroid carcinoma cell line.
Topics: Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Protein | 2014 |
Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA).
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma; Cell Line, Tumor; Cell Proliferation; Chloro | 2015 |
Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Carcinoma; Carcin | 2016 |
Generation of Novel Thyroid Cancer Stem-Like Cell Clones: Effects of Resveratrol and Valproic Acid.
Topics: Animals; Antioxidants; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Enzyme Inhibito | 2016 |
Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells.
Topics: Analysis of Variance; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcin | 2008 |
Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery.
Topics: Carcinoma; Cisplatin; Combined Modality Therapy; Doxorubicin; Humans; Male; Middle Aged; Thyroid Gla | 2009 |
Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Cell Cycle | 2009 |
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
Topics: Adenocarcinoma, Follicular; Blotting, Western; Carcinoma, Papillary; Cell Cycle; Cell Proliferation; | 2009 |
Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
Topics: Acetylcysteine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cell Survival; | 2009 |
Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride.
Topics: Cell Division; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Histone Deacetylase Inhi | 2010 |
Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors.
Topics: Adenocarcinoma, Follicular; Adenocarcinoma, Papillary; Antimetabolites, Antineoplastic; Azacitidine; | 2011 |
Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells.
Topics: Carcinoma; Carcinoma, Papillary; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, | 2004 |
Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells.
Topics: Apoptosis; Carcinoma, Papillary; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Line, T | 2005 |
Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells.
Topics: Adenocarcinoma, Follicular; Adenocarcinoma, Papillary; Apoptosis; Apoptosis Regulatory Proteins; Cel | 2005 |
Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
Topics: Acetylation; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Carcinoma; Caspase 3; Cell Cycle; | 2006 |
Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines.
Topics: Acetylation; Acetyltransferases; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2007 |